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responsibility of XAbstract In the eradication therapy ofHelicobacter pylori changes of antibiotics as these concentrations
or amount in the stomach after oral administration were not clear. A simple and accurate method for
determining the concentration of metronidazole (MTZ) in homogenate of rat stomach was developed in
order to obtain basic data to design a pharmaceutical preparation having targeting ability to the surface
of gastric-mucosa. This method included a deproteinization process by methanol, separation with
reversed-phase high-performance liquid chromatography, and detection with an ultraviolet wavelength
of 370 nm. Regression analysis showed that the method was linear over a standard curve range from
5 mg/mL to 2000 mg/mL. The inter-day precision and accuracy values between the ranges were 5.0% or
better and 7.5 to 5.2%, respectively. The newly developed method was applied to an analysis of gastric
samples after oral administration of MTZ at a dose of 5 mg/kg. It was found that the residual MTZ in
the stomach was determined within 5 h after dosing. This method is useful for monitoring MTZ in
stomach after its oral administration to rats.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
.007
4 3465; fax:þ81 287 24 3521.
oo.co.jp (T. Tokumura).
i’an Jiaotong University.1. Introduction
Gastric Helicobacter pylori (H. pylori) infection is associated with
chronic (type B) gastritis and peptic ulcer [1–3]. H. pylori is often
observed to adhere to the antral epithelium of the human
stomach and gastric metaplasia in the duodenum. Gastric and
duodenal ulcers are believed to develop as the result of damage to
the gastric mucosa by cytotoxic substances (ammonia, cytotoxin,
etc.) produced by H. pylori [4]. Recent studies have providedlsevier B.V. All rights reserved.
Fig. 1 Chemical structure of metronidazole.
Determination of metronidazole in a rat stomach by HPLC 379evidence that cytotoxin-associated gene A product (cagA)-positive
H. pylori plays a causal role for the development of gastric
carcinoma [5–7]. Therefore, the eradication of H. pylori is
considered to be very important. The primary eradication
therapy for H. pylori in Japan which is a triple therapy using
amoxicillin, clarithromycin and proton pump inhibitor was
started in 2000 with the therapy approved for health insurance
coverage [8]. However, because of the increase of incomplete
eradication, the second-line eradication therapy was approved in
2007 [8]. In the eradication therapy, metronidazole (MTZ) is
used in the place of clarithromycin. The H. pylori strains with
clarithromycin resistance signiﬁcantly increase more and more,
so the importance of the second-line eradication therapy also
increases [8]. The pharmaceutical preparations used in the
eradication therapy were not developed for the eradication
therapy. For example in Japan, the pharmaceutical preparations,
Pasetocin Tablets 250 for amoxicillin and Flagyl for MTZ, were
developed for various bacterial infections in 1981 and 1963,
respectively. These preparations were designed to have the effect
through the blood circulation after GI absorption. For H. pylori
eradication therapy, an intragastric local attack is expected [9].
From the point of view of pharmaceutical preparations design,
the preparations used are not optimal preparations [10].
In order to design the pharmaceutical preparations, the
information of drug amount and/or concentrations in stomach
was very important in this case. However, the information for
the amount and/or concentration of drugs in stomach after
oral administration of antibiotics used for the eradication
therapy was not enough for both of human and experimental
animals. Therefore, we tried to develop the determination
method of MTZ in rat stomach to study its intragastric
behavior of rats. Many kinds of determination methods of
MTZ using HPLC have been reported [11–13]. However, these
methods could not apply to its determination from rat
stomach, because the samples have many peaks from feed
and its digests which were not constant. In order to determine
MTZ in stomach further investigations were required.
This paper describes a simple high-performance liquid
chromatographic (HPLC) procedure for determining the
intragastric amount of MTZ in rats, and the result of the
preliminary study on its intragastric behavior in rats.2. Materials and methods
2.1. Chemicals and solvents
Metronidazole (MTZ, Fig. 1) was purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan). Other chemicals
were of special reagent grade or HPLC grade.
2.2. Apparatus and chromatographic conditions
The HPLC system consisted of a Model LC-10AS pump,
equipped with a Model SCL-10A system controller, a Model
SPD-10A UV spectrophotometric detector, a Model CTO-10A
column oven, a Model C-R7A Chromatopac, and a Model SIL-
10A autoinjector, all from Shimadzu corpolation (Kyoto,
Japan). The mobile phase was methanol–water–perchloric acid
(60%)—sodium perchlorate monohydrate (50:950:1:5, V/V/V/
W). The chromatographic column was a YMC Pack AM12S05
ODS (150 mm 6 mm I.D., particle diameter 5 mm) obtainedfrom YMCCo. Ltd. (Kyoto, Japan). The ﬂow rate, wavelength for
determination, and temperature of the column were 1 mL/min,
370 nm, and 40 1C, respectively. The wavelength was chosen
because MTZ had absorbance at around 370 nm and peaks
monitored around 370 nm from endogenous and feed were smaller.
2.3. Animal study and preparation of stomach homogenate
Male Sprague-Dawley rats were used. All rats (270–330 g body
weight) were allowed free access to water and food. MTZ was
dissolved in a 0.5% methylcellulose solution to make the solution
with a concentration of 25 mg/mL of MTZ. A 0.2 mL/kg of the
solution was administered orally. The stomachs were withdrawn
from the abdomen after the rats were anesthetized with ether. When
the stomachs were withdrawn, the esophagus of the upper side of
the stomach and the duodenum of the lower side of the stomach
were ligated. The stomachs withdrawn were washed out with saline
and weighed. A ﬁve times saline of each stomach as weight was
added to the stomach and that was homogenized. All animal
experiments were carried out according to ‘Guiding Principles for
the Care and Use of Laboratory Animals, Hoshi University’.
2.4. Preparation of standards
Rat stomachs not administered the drug were withdrawn,
washed out with saline, and weighed. The drug-free homogenates
were prepared according to the method described above. MTZ
(100 mg) was dissolved in 50 mL of the drug-free homogenate.
This homogenate was used as the standard homogenate.
2.5. Calibration curve samples
The standard homogenate of MTZ was diluted with the drug-
free homogenate to obtain homogenates containing MTZ at the
concentrations of 5, 10, 25, 50, 100, 500, 1000, and 2000 mg/mL.
For the daily standard curves, a 5 mL of the homogenate at each
concentration was prepared, and the curves were prepared by
analyzing duplicate at each concentration.
2.6. Assay procedures
Stomach homogenates which were 1.0 mL or 2.5 mL were
added to glass tubes, and the weight of the homogenates was
measured. Exactly twice volume of methanol, 2.0 or 5.0 mL,
as much as the volume of stomach homogenates was added to
the tube cooled in an ice-bath. The mixture was stirred on a
vortex mixer for 10 s and centrifuged at 3000 rpm for 10 min;
10 mL of the supernatant was injected into the chromatograph.
The animal study and assay were performed on the same day.
2.7. Calculations
The peak area of MTZ in the HPLC proﬁles was measured. A
calibration curve was established by comparing the peak-area
M. Kubodera et al.380against the concentration of MTZ in the standards. The slope
and intercept of the curve were calculated using weighted
(1/Y2) linear regression. The concentration of MTZ in the
experimental samples was calculated using the equation X (mg/
mL)¼(Yb)/a, where Y is the peak area of MTZ in an
experimental sample and b (intercept) and a (slope) are
constants generated by linear regression analysis of the
calibration curve data.2.8. Recovery
The relative recovery of MTZ was determined by comparing
the peak-area ratio obtained from the treatment of the
stomach homogenates standards with that of the standard
solutions prepared with physiological saline solution at the
equivalent concentrations, 10, 50, and 100 mg/mL.Table 1 Intra-day precision and accuracy of the mea-
surement of metronidazole in rat stomach.
Actual
concentration
Concentration
found (mg/mL)
Precision Accuracy
(mg/mL) (mean7SD, n¼5) (%) (%)
5 4.970.1 1.3 1.52.9. Calculations of MTZ in rat stomach
Concentrations of MTZ in the homogenates were calculated from
the calibration curve. After the concentration was calculated, the
amount of MTZ in stomach was calculated from the weight of
homogenates used for assay, and the weight of the homogenate
prepared. The amount of MTZ in the homogenate prepared was
equal to MTZ in the rat stomach. The remaining percent (%) was
calculated from MTZ in the rat stomach and the oral dose of
MTZ (mg) for each rat.Fig. 2 HPLC chromatograms of stomach homogenates from rats
containing MTZ (A) drug-free stomach; (B) gastric sample spiked
with MTZ at 25 mg/mL; (C) gastric sample from a rat 1 h after
oral administration of MTZ (concentration of MTZ is 14.9 mg/
mL). The arrow shows the peak of MTZ.3. Results and discussion
3.1. Measurement of MTZ by HPLC
Typical chromatograms of MTZ obtained under the condi-
tions described above are shown in Fig. 2. The retention time
of MTZ was approximately 9.7 min. The chromatogram of
drug-free stomach homogenate showed no detectable inter-
ference by endogenous substances in the stomach.
Linear regression analysis gave a slope, intercept and
correlation coefﬁcient of Y¼347.616X–49.117, r¼0.999, and
weight¼1/Y2, as the calibration curve. The intra-day precision
and accuracy were determined by analyzing ﬁve replicates at
each drug concentration. The precision and accuracy of this
method are shown in Table 1. The precision was found to
range from 0.7% to 3.6%. The accuracy value ranged from
6.8% to 4.8%.
The inter-day precision and accuracy were determined by
analyzing duplicates at each standard concentration over six10 10.170.3 2.7 0.6
25 26.070.4 1.5 4.1
50 52.470.9 1.7 4.8
100 104.673.8 3.6 4.6
500 497.473.5 0.7 0.5
1000 975.4713.3 1.4 2.5
2000 1863.3745.7 2.5 6.8
Precision and accuracy values were calculated by the following
equations.
Precision (%)¼ (SD/mean) 100.
Accuracy (%)¼ ((concentration found—actual concentration)/
actual concentration) 100.
Table 2 Inter-day precision and accuracy of the measure-
ment of metronidazole in rat stomach.
Actual
concentration
Concentration
found (mg/mL)
Precision Accuracy
(mg/mL) (mean7SD, n¼12) (%) (%)
5 4.970.2 3.4 1.1
10 10.170.5 5.0 0.7
25 25.570.4 1.7 2.1
50 51.470.8 1.6 2.8
100 105.271.8 1.7 5.2
500 509.275.4 1.1 1.8
1000 986.6713.3 1.3 1.3
2000 1850.7733.1 1.8 7.5
Precision and accuracy values were calculated by the following
equations.
Precision (%)¼ (SD/mean) 100.
Accuracy (%)¼ ((concentration found—actual concentration)/
actual concentration) 100.
Table 3 Intragastric remaining MTZ after its oral administration to rats at the dose of 5 mg/kg.
Time after
oral dosing (h)
Concentration of MTZ
in homogenates (mg/mL)
MTZ in the
stomach (mg)a
Remaining percent
in the stomachb(%)
0.0833 21.5 1.26 88.3
1 14.9 0.83 56.2
3 13.4 0.42 29.9
5 7.2 0.17 11.6
aThe amount of MTZ in the stomach was calculated from the weight of homogenates used for assay, and the weight of the homogenate
prepared.
bThe remaining percent (%) was calculated from MTZ in the rat stomach and the oral dose of MTZ (mg) for each rat.
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Table 2. The precision from 5 to 2000 mg/mL was 5.0% or
better. The accuracy ranged from 7.5% to 5.2%. The values
of the intra-day and inter-day precision and accuracy were
acceptable. The lower limit of quantiﬁcation was established
from the validation data as shown in Tables 1 and 2, because
the precision was lower than 10% and the accuracy was
existent from 10% to 10% at 5 mg/mL.
The recovery rates of each concentration (100, 50, and
10 mg/mL) were 91.971.8% (mean7SD, n¼3), 93.775.0%,
and 90.574.0%, respectively. The minimum inhibitory concentra-
tion (MIC) of MTZ for H. pylori was reported as 8 mg/mL [14].
Therefore, this method is useful to quantify gastric concentration
of MTZ.
3.2. Remaining MTZ in the stomach of rats
Table 3 shows the remaining MTZ after oral administration to
rats at the dose of 5.0 mg/kg. The MTZ apparently decreased
with time. This method was found to be useful for determining
MTZ in the stomach.4. Conclusion
We developed a fast, simple and accurate method for measuring
MTZ in the stomach of rats. This method involves deproteiniza-
tion using methanol and reversed-phase high-performance liquid
chromatography with ultraviolet detection. It has been applied to
an analysis of MTZ in the stomach after the oral administration
of MTZ to rats at a dose of 5 mg/kg.
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